No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Clinical Infectious Diseases

Volumn 63, Issue 9, 2016, Pages 1202-1204

  Sulkowski, Mark S ^a   Chuang, Wan Long ^b   Kao, Jia Horng ^c   Yang, Jenny C ^d   Gao, Bing ^d   Brainard, Diana M ^d   Han, Kwang Hyub ^e   Gane, Edward ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d GILEAD SCIENCES   (United States)

^e Yonsei University College of Medicine   (South Korea)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

ALT flare; HBV reactivation; HCV HBV coinfection

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; LEDIPASVIR PLUS SOFOSBUVIR; VIRUS DNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; TAIWAN; VIRUS LOAD; VIRUS REACTIVATION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HEPATITIS B; MIDDLE AGED; MIXED INFECTION; PHASE 3 CLINICAL TRIAL; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; VIRUS ACTIVATION;

EID: 84994500704     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw507     Document Type: Article

References (12)

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49:S156-65.
2. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703-11.
3. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Reports 2015; 9:164.
4. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015; 61:1304-6.
5. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 2016; 78:27-30.
6. Balagopal A, Thio CL. Another call to cure hepatitis B. Clin Infect Dis 2015; 61:1307-9.
7. Ozaras R, Sunbul M, Parlak M, Bodur H, Leblebicioglu H. Treating HBV/HCV coinfected patients with direct-acting HCV antivirals only is not safe. Hepatology 2016; doi:10.1002/hep.28592.
8. Chuang WL, Chien RN, Peng CY, et al. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol 2016; 31:1323-9.
9. Lim YS, Ahn SH, Lee KS, et al. A phase IIIb study of ledipasvir/sofosbuvir fixeddose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology Int 2016; doi:10.1007/s12072-016-9726-5.
10. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3:57-62.
11. Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antiviral Ther 2016; doi:10.3851/IMP3066.
12. Murrill C, Weeks H, Castrucci B, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 2002; 92:385-7.